Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Both Mounjaro (tirzepatide) and Ozempic (semaglutide) have transformed weight loss treatment by mimicking natural appetite-control hormones. However, tirzepatide activates two distinct pathways in the body, while semaglutide activates one, leading to different outcomes for different people. PlexusDx offers both medications through licensed 503A compounding pharmacies, and the choice between them depends on your individual biology and health goals.

Understanding the Mechanism: Single vs Dual Hormone Pathway

Semaglutide (Ozempic) works by activating the GLP-1 receptor alone, which signals fullness to the brain and slows stomach emptying. This single-pathway approach has been proven effective across millions of users and remains the most studied weight loss medication. Tirzepatide (Mounjaro) activates both the GLP-1 receptor and the GIP receptor simultaneously, creating a dual-hormone effect that may amplify appetite suppression and metabolic improvements.

Clinical trials show tirzepatide produced greater average weight loss than semaglutide at comparable doses in head-to-head studies. In the SURMOUNT trials, participants on tirzepatide lost approximately 20–22% of body weight over 72 weeks, compared to 15–17% on semaglutide over similar timeframes. However, individual responses vary significantly based on genetic factors, body composition, and metabolic health.

Weight Loss Results: What the Research Shows

Tirzepatide demonstrated superior weight loss in direct comparison studies, with average losses ranging from 15 to 22 pounds more than semaglutide in some patient groups. The dual-receptor activation appears to produce stronger sustained appetite reduction and may improve blood sugar control more effectively. Semaglutide remains highly effective for weight loss, with most users experiencing 10–15% body weight reduction within 6 months of treatment.

Your individual results depend on adherence, lifestyle factors, and how your body's peptide pathways respond to each medication. PlexusDx offers the Precision Peptide Genetic Test to map your unique peptide genetics across 14 pathways and 49 peptides, helping identify which mechanism may work best for your biology before you start treatment. This personalization removes guesswork from selecting between tirzepatide and semaglutide.

Side Effects and Tolerability Comparison

Both medications cause similar gastrointestinal side effects early in treatment, including nausea, vomiting, and constipation, which typically resolve within 2–4 weeks. Tirzepatide users report slightly higher rates of nausea during dose escalation, though serious adverse events remain rare with both compounds. Semaglutide has been used clinically longer, providing more long-term safety data across diverse populations.

Rare but serious risks include pancreatitis and thyroid concerns, documented with both medication classes. Most side effects are dose-dependent and manageable through gradual titration. PlexusDx pharmacists monitor your response and adjust your dose without increasing your monthly price—your dose may go up, but your price won't, whether you start on semaglutide injection at $149/month or tirzepatide injection at $249/month.

Cost, Availability, and Personalization at PlexusDx

PlexusDx compounded semaglutide injection starts at $149 per month across all commitment tiers, while compounded tirzepatide injection starts at $249 per month. Both medications are prepared by licensed 503A compounding pharmacies and shipped to all 50 states without insurance requirements or membership fees. Oral formulations are also available at higher price points for patients who prefer injections to pills.

PlexusDx adds precision through the Precision Peptide Genetic Test ($99 add-on after your first month), which identifies your unique variants in key genes like GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313. These insights show how your body responds to dual-pathway vs single-pathway activation, helping confirm whether tirzepatide or semaglutide aligns better with your genetic makeup. HSA and FSA accounts cover both medications and genetic testing.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Which medication causes more weight loss—Mounjaro or Ozempic?

Clinical trials show tirzepatide (Mounjaro) produces approximately 3–7 pounds more weight loss on average than semaglutide (Ozempic) over 72 weeks. However, individual results vary widely based on genetics, adherence, and lifestyle. PlexusDx genetic testing can help predict which mechanism may work better for your unique peptide pathways.

Does tirzepatide work faster than semaglutide?

Tirzepatide typically shows measurable appetite suppression within 2–3 weeks due to dual-pathway activation. Semaglutide may take slightly longer to reach full effect, though both medications require 8–12 weeks of consistent dosing to assess true efficacy. PlexusDx pharmacists monitor your weekly response and adjust your dose to optimize results.

Can I switch from Ozempic to Mounjaro if I'm not seeing results?

Yes, switching between semaglutide and tirzepatide is medically appropriate if you plateau or experience inadequate weight loss after 12+ weeks. PlexusDx supports medication changes within your monthly plan at no additional cost. A consultation with your PlexusDx care team ensures a safe transition with proper dose calibration.

Are compounded versions of these medications as effective as brand-name versions?

PlexusDx compounded semaglutide and tirzepatide are prepared by licensed 503A compounding pharmacies using pharmaceutical-grade ingredients with bioequivalent potency to brand-name Ozempic and Mounjaro. Compounding allows for flexible dosing and personalized formulations that branded medications cannot offer.

How does PlexusDx genetic testing help choose between Mounjaro and Ozempic?

The Precision Peptide Genetic Test maps your GIPR, GLP1R, FTO, and MC4R variants across 14 pathways and 49 peptides. Patients with specific GIP receptor variants (GIPR rs1800437) may show stronger response to tirzepatide's dual activation, while others respond excellently to single-pathway semaglutide.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves